FDA Revamps Rules to Stop Infections from Body Part Swaps
Published Date: 5/5/2025
Notice
Summary
The FDA is updating its safety advice for people and companies that handle human cells and tissues used in medical treatments. They’re pulling back old rules about stopping infections like sepsis and tuberculosis and sharing new draft versions to get feedback. This means safer products and a chance for industry to weigh in before final rules are set.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Safer human cell and tissue products
The FDA is updating safety advice for people who receive or handle human cells and tissues used in medical treatments by withdrawing prior final guidances and issuing new draft guidances addressing transmission of sepsis and Mycobacterium tuberculosis. The change is intended to reduce the risk that these infections are passed through human cells, tissues, and cellular and tissue‑based products.
Industry can comment on new draft guidances
The FDA withdrew two final guidances titled "Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue‑Based Products (HCT/Ps)" and "Recommendations to Reduce the Risk of Transmission of Mycobacterium Tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue‑Based Products (HCT/Ps)" and reissued them as draft guidances so people and companies that handle HCT/Ps can provide feedback before final rules are set.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12167 — Andrew Jonathan Morgan: Final Debarment Order
Andrew Jonathan Morgan is officially banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime related to drug importation. He didn’t respond to the FDA’s notice, so the ban started on June 17, 2026, and he can apply to end it anytime. This means no drug imports from him for a while, keeping things safe and legal.
2026-12165 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Ingestible Gastrointestinal Blood Detection Capsule
The FDA is officially putting the ingestible gastrointestinal blood detection capsule into Class II, meaning it now has special safety rules but fewer hurdles than before. This change helps patients get access to this cool, innovative device faster and keeps it safe and effective. The new classification is effective June 17, 2026, and could save time and money for makers and users alike.
2026-12166 — Medical Devices; Radiology Devices; Classification of the Radiological Machine Learning-Based Quantitative Imaging Software With Predetermined Change Control Plan
The FDA is officially putting radiology software that uses machine learning and has a set plan for updates into a safer, easier-to-manage category called Class II. This change helps make sure the software is safe and effective while speeding up patient access to cool new tech. It’s been effective since early 2023, so companies can expect fewer hoops to jump through without extra costs or delays.
2026-11966 — Forms FDA 3542a and FDA 3542: Questions and Answers; Draft Guidance for Industry; Availability
The FDA just dropped a draft guide to help businesses fill out Forms FDA 3542a and FDA 3542 without confusion. If you submit these forms, this guide answers your top questions and makes the process smoother. You’ve got until August 14, 2026, to send in your feedback before the FDA finalizes the guide—no extra costs, just clearer steps!
2026-11998 — Amendment and Revocation of Organizational Information Regulations
The FDA is updating its rules to point everyone to its website for the latest contact and organizational info, ditching old, unnecessary regulations. This makes it easier for the public to find accurate info all in one place, starting June 15, 2026. If you interact with the FDA, expect smoother access with no extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
Previous / Next Documents
Previous: 2025-07751 — Norfolk Southern Railway Company-Trackage Rights Exemption-CSX Transportation, Inc.
Norfolk Southern Railway (NSR) got special permission to use CSX Transportation’s tracks for about 95 miles to reroute trains while a tunnel in Baltimore is being fixed. Now, NSR and CSX have agreed to end this temporary track-sharing deal once the project is done, and the Surface Transportation Board is approving that plan. This means NSR won’t need extra approvals later, keeping things smooth and simple for everyone involved.
Next: 2025-07754 — Foreign-Trade Zone (FTZ) 102, Notification of Proposed Production Activity; Tight Line Composites LLC; (Carbon Fiber Profiles for Wind Turbine Spar Caps); Earth City, Missouri
Tight Line Composites in Earth City, Missouri, wants to make carbon fiber parts for wind turbines inside a special Foreign-Trade Zone (FTZ 102). This lets them use certain imported materials with lower or no import taxes, saving money and speeding up production. Public comments are open until June 16, 2025, before the government gives the final thumbs-up.